KalVista Pharmaceuticals (DE:4XC1)
FRANKFURT:4XC1
4XC1 Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
4XC1 Stock 12 Month Forecast
Average Price Target
€30.50
▲(89.54% Upside)
| Highest Price Target€36.01 | Average Price Target€30.50 | Lowest Price Target€24.01 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
€33.75
Buy
109.77%
Upside
Reiterated
04/06/26
Stifel Nicolaus
€33.75→€36.35
Buy
125.90%
Upside
Reiterated
03/29/26
H.C. Wainwright
€23.37→€32.02
Buy
99.01%
Upside
Assigned
03/26/26
Citizens JMP
€25.1→€24.23
Buy
50.60%
Upside
Reiterated
03/26/26
Needham
€27.69→€31.16
Buy
93.63%
Upside
Reiterated
03/25/26
TD Cowen
€30.29
Buy
88.25%
Upside
Reiterated
03/25/26
Bank of America Securities
€27.69
Buy
72.12%
Upside
Reiterated
03/25/26
Jefferies
€32.89
Buy
104.39%
Upside
Reiterated
01/09/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
€33.75
Buy
109.77%
Upside
Reiterated
04/06/26
Stifel Nicolaus
€33.75→€36.35
Buy
125.90%
Upside
Reiterated
03/29/26
H.C. Wainwright
€23.37→€32.02
Buy
99.01%
Upside
Assigned
03/26/26
Citizens JMP
€25.1→€24.23
Buy
50.60%
Upside
Reiterated
03/26/26
Needham
€27.69→€31.16
Buy
93.63%
Upside
Reiterated
03/25/26
TD Cowen
€30.29
Buy
88.25%
Upside
Reiterated
03/25/26
Bank of America Securities
€27.69
Buy
72.12%
Upside
Reiterated
03/25/26
Jefferies
€32.89
Buy
104.39%
Upside
Reiterated
01/09/26
Best Analysts Covering KalVista Pharmaceuticals
3 Months
xxx
Success Rate
14/23 ratings generated profit
Average Return
+12.60%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +12.60% per trade.
1 Year
Success Rate
20/23 ratings generated profit
Average Return
+28.50%
reiterated a buy rating 6 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +28.50% per trade.
2 Years
xxx
Success Rate
22/23 ratings generated profit
Average Return
+43.89%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +43.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
4XC1 Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
17
23
16
15
8
Buy
1
0
0
1
1
Hold
1
28
48
58
31
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
51
64
74
40
Each month's total comprises the sum of three months' worth of ratings.
4XC1 Financial Forecast
4XC1 Stock Forecast FAQ
What is DE:4XC1’s average 12-month price target, according to analysts?
Based on analyst ratings, KalVista Pharmaceuticals’s 12-month average price target is 30.50.
What is DE:4XC1’s upside potential, based on the analysts’ average price target?
KalVista Pharmaceuticals has 89.54% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KalVista Pharmaceuticals a Buy, Sell or Hold?
KalVista Pharmaceuticals has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is KalVista Pharmaceuticals’s share price target?
The average share price target for KalVista Pharmaceuticals is 30.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €36.01 ,and the lowest forecast is €24.01. The average share price target represents 89.54% Increase from the current price of €16.09.
The highest analyst share price target is €36.01 ,and the lowest forecast is €24.01. The average share price target represents 89.54% Increase from the current price of €16.09.
What do analysts say about KalVista Pharmaceuticals?
KalVista Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of KalVista Pharmaceuticals?
To buy shares of DE:4XC1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.